To crack the code of FSHD, patients are absolutely essential
All of the breakthroughs—the discovery of the genetic causes, understanding why some patients vary so greatly in the severity of their symptoms, teasing out the biochemical pathways that could point to future treatments—were made because patients stepped up to the plate.
Too often, we hear patients say they’ll volunteer when there’s a treatment. But we will never get to a treatment unless patients participate in fundamental research now. FSHD is uniquely human, so no laboratory mouse can ever fully model the disease. The genetic “package” that causes FSHD is found only in people. We owe an enormous debt to the patients who give DNA samples. Who submit to long interviews and exhausting physical tests. Allow a surgeon to cut out a small muscle sample. Who fight claustrophobia to lie in the narrow bore of an MRI machine.
Equally important are patients’ family members, both affected and unaffected, who provide the best experimental controls because of their shared genetic and environmental backgrounds. A parent or sibling who has very mild symptoms may hold the key to understanding the factors that protect against the full-blown development of FSHD symptoms in a more severely affected family member.
We are more hopeful today than ever before that a treatment is within sight. We cannot guarantee when that treatment will arrive, but here’s one thing we guarantee: If you volunteer for research, your participation will without question help move us a step closer to that day.
Scientific Overview of FSHD
Read the latest on wikipedia
Glossary of Scientific Terms
FSH Society funds $393,489 for five (5) new research awards for the August 2012 grant cycle!
FSH Society Scientific Advisory Board (SAB) recommends and Board of Directors funds $393,489 for five (5) new research awards for the August 2012 grant cycle! PDF
The FSH Society Answers Questions About the New Gene for FSH Muscular Dystrophy
Boston, MA / January 24, 2013 Facioscapulohumeral muscular dystrophy (FSHD) is a disease most people have never heard of, even though it is one of the most common forms of… Read More »
GlaxoSmithKline PLC (GSK) announces partnership to develop therapeutics to treat FSHD
GlaxoSmithKline PLC (GSK) announces partnership to develop therapeutics to treat FSHD. The goal of the new agreement is to develop a small-molecule-based medicine to potentially reverse FSHD
Progress in FSHD Muscular Dystrophy Research Hailed at International Meeting
San Francisco, CA / November 08, 2012 Just two decades ago, the scientific world largely ignored a mysterious disease that causes muscles to weaken throughout the body. Called fascioscapulohumeral muscular… Read More »